{"id":7233,"date":"2022-10-12T09:15:08","date_gmt":"2022-10-12T13:15:08","guid":{"rendered":"https:\/\/groupedevonian.com\/?p=7233"},"modified":"2024-01-05T10:07:17","modified_gmt":"2024-01-05T15:07:17","slug":"devonian-presentera-les-resulats-cliniques-de-la-phase-2-du-thykamine-au-6th-dermatology-drug-development-summit-for-inflammatory-skin-diseases","status":"publish","type":"post","link":"https:\/\/groupedevonian.com\/fr\/devonian-presentera-les-resulats-cliniques-de-la-phase-2-du-thykamine-au-6th-dermatology-drug-development-summit-for-inflammatory-skin-diseases\/","title":{"rendered":"DEVONIAN PR\u00c9SENTERA LES R\u00c9SULATS CLINIQUES DE LA PHASE 2 DU THYKAMINE\u2122 AU 6th DERMATOLOGY DRUG DEVELOPMENT SUMMIT FOR INFLAMMATORY SKIN DISEASES"},"content":{"rendered":"<h1>DEVONIAN PR\u00c9SENTERA LES R\u00c9SULATS CLINIQUES DE LA PHASE 2 DU THYKAMINE\u2122 AU 6th DERMATOLOGY DRUG DEVELOPMENT SUMMIT FOR INFLAMMATORY SKIN DISEASES.<\/h1>\n<p><strong>QU\u00c9BEC, le\u00a0 12 octobre, 2022\u2013 <\/strong>Groupe Sant\u00e9 Devonian inc.<strong> (\u00ab Devonian \u00bb ou la \u00ab Soci\u00e9t\u00e9 \u00bb) (TSXv: GSD ; OTCQB: DVHGF), <\/strong>une soci\u00e9t\u00e9 biopharmaceutique botanique en stade avanc\u00e9 de d\u00e9veloppement ax\u00e9e sur l\u2019\u00e9laboration d\u2019un portefeuille unique de m\u00e9dicaments d\u2019ordonnance et de produits cosm\u00e9ceutiques d\u2019origine botanique, a annonc\u00e9 aujourd&rsquo;hui sa pr\u00e9sence lors du prochain 6th Annual Dermatology Drug Development Summit for Inflammatory Skin Diseases (\u00ab<strong>ADDD<\/strong>S\u00bb) qui se tiendra du 1er au 3 novembre 2022 \u00e0 Boston, MA, \u00c9tats-Unis.<\/p>\n<p>Au cours de ce sommet, la Soci\u00e9t\u00e9 pr\u00e9sentera les r\u00e9sultats de l\u2019essai clinique de phase 2 du Thykamine\u2122 en dermatite atopique ainsi que et d&rsquo;autres applications th\u00e9rapeutiques ciblant des inflammations dermatologiques.<\/p>\n<p>Les d\u00e9tails de la pr\u00e9sentation orale sont les suivants:<br \/>\n<strong>Titre:<\/strong> Thykamine\u2122 A New Botanical Drug: A Serious Candidate for the treatment of Atopic dermatitis &amp; beyond<br \/>\n<strong>Session<\/strong>: Emerging Clinical Candidates &amp; Therapeutic Options<br \/>\n<strong>Date\/Heure:<\/strong> Jeudi, le 3 novembre 2022, 13:40pm-14:10pm (HNE)Des informations suppl\u00e9mentaires, y compris le guide complet de l&rsquo;\u00e9v\u00e9nement ADDDS, sont disponibles sur <a href=\"https:\/\/dermatology-drugdevelopment.com\">https:\/\/dermatology-drugdevelopment.com<\/a><\/p>\n<p><strong>Au sujet du Thykamine<sup>MC<br \/>\n<\/sup><\/strong>Thykamine<sup>mc<\/sup>, le premier produit pharmaceutique issu de la plateforme SUPREX<sup>MC<\/sup> de Devonian, est un produit hautement innovant pour la pr\u00e9vention et le traitement des probl\u00e8mes de sant\u00e9 li\u00e9s \u00e0 l&rsquo;inflammation et au stress oxydatif, notamment la colite ulc\u00e9reuse, la dermatite atopique, le psoriasis, la polyarthrite rhumato\u00efde et d&rsquo;autres maladies auto-immunes. Les propri\u00e9t\u00e9s anti-inflammatoires, anti-oxydantes et immunomodulatrices du Thykamine<sup>MC<\/sup> ont \u00e9t\u00e9 d\u00e9montr\u00e9es par un nombre consid\u00e9rable d&rsquo;\u00e9tudes in vitro et in vivo ainsi que par une \u00e9tude clinique de phase IIa chez des patients atteints colite ulc\u00e9reuse distale l\u00e9g\u00e8re \u00e0 mod\u00e9r\u00e9e et dans une \u00e9tude clinique de phase II chez des patients atteints de dermatite atopique l\u00e9g\u00e8re \u00e0 mod\u00e9r\u00e9e. Le Thykamine<sup>MC<\/sup> et la plateforme SUPREX<sup>MC<\/sup> sont prot\u00e9g\u00e9es par plusieurs brevets en Am\u00e9rique du Nord, en Europe et en Asie.<\/p>\n<p><strong>Au sujet de Devonian<br \/>\n<\/strong>Groupe Sant\u00e9 Devonian inc. est une soci\u00e9t\u00e9 biopharmaceutique botanique en stade avanc\u00e9 de d\u00e9veloppement qui emploie une strat\u00e9gie novatrice ciblant des besoins m\u00e9dicaux non combl\u00e9s. La principale strat\u00e9gie de Devonian est de d\u00e9velopper des m\u00e9dicaments d\u2019ordonnance d\u2019origine botanique pour le traitement des maladies inflammatoires auto-immunes incluant, mais sans s\u2019y limiter, la colite ulc\u00e9reuse et la dermatite atopique. Fond\u00e9 sur une assise de 15 ann\u00e9es de recherche, l\u2019objectif de Devonian est \u00e9galement appuy\u00e9 par les directives r\u00e9glementaires de la FDA, l\u2019agence am\u00e9ricaine des produits alimentaires et m\u00e9dicamenteux, favorisant un processus de d\u00e9veloppement de produits m\u00e9dicamenteux botaniques d\u2019ordonnance plus efficient que celui des m\u00e9dicaments d\u2019ordonnance classique.<\/p>\n<p>Devonian est \u00e9galement impliqu\u00e9e dans le d\u00e9veloppement de produits cosm\u00e9ceutiques de grande valeur en s&rsquo;appuyant sur la m\u00eame approche exclusive que celle utilis\u00e9e avec leurs offres pharmaceutiques.<\/p>\n<p>Devonian est cot\u00e9e \u00e0 la Bourse de croissance TSX (<strong>TSXv:GSD<\/strong>) ainsi que sur la bourse de croissance OTCQB (<strong>OTCQB\u00a0: DVBHGF<\/strong>).<\/p>\n<p>Pour plus de d\u00e9tails, visitez le <a href=\"https:\/\/groupedevonian.com\/fr\/\">www.groupedevonian.com<\/a><\/p>\n<p><strong>\u00c9nonc\u00e9s prospectifs<br \/>\n<\/strong>Le pr\u00e9sent communiqu\u00e9 renferme des \u00e9nonc\u00e9s prospectifs sur les objectifs, les strat\u00e9gies et les activit\u00e9s de Devonian. Ces \u00e9nonc\u00e9s prospectifs sont assujettis \u00e0 certains risques et incertitudes. Ces \u00e9nonc\u00e9s sont de nature \u00ab\u2009prospective\u2009\u00bb puisqu\u2019ils sont fond\u00e9s sur nos attentes pr\u00e9sentes \u00e0 l\u2019\u00e9gard des march\u00e9s dans lesquels nous exer\u00e7ons nos activit\u00e9s et sur diverses estimations et hypoth\u00e8ses. Les \u00e9v\u00e9nements ou les r\u00e9sultats r\u00e9els sont susceptibles de diff\u00e9rer consid\u00e9rablement de ceux pr\u00e9vus dans le cadre des \u00e9nonc\u00e9s prospectifs si des risques connus ou inconnus affectent nos activit\u00e9s ou si nos estimations ou nos hypoth\u00e8ses s\u2019av\u00e8rent inexactes. Ces risques, estimations et hypoth\u00e8ses incluent, mais sans s\u2019y limiter, l\u2019approbation de la Bourse de croissance TSX en lien avec l\u2019\u00e9mission des Unit\u00e9s, la capacit\u00e9 de Devonian d\u2019assurer le d\u00e9veloppement, la fabrication et la commercialisation de produits pharmaceutiques et dermo-cosm\u00e9tiques \u00e0 valeur ajout\u00e9e, la disponibilit\u00e9 de ressources financi\u00e8res pour mener \u00e0 bien des projets de recherche et d\u00e9veloppement, le succ\u00e8s et la dur\u00e9e d\u2019\u00e9tudes cliniques, la capacit\u00e9 de Devonian de se pr\u00e9valoir des occasions d\u2019affaires dans l\u2019industrie pharmaceutique et dermo-cosm\u00e9tique, les incertitudes li\u00e9es au processus de r\u00e9glementation et tout changement du contexte \u00e9conomique. Vous trouverez une analyse plus exhaustive des risques qui pourraient faire en sorte que les \u00e9v\u00e9nements ou r\u00e9sultats r\u00e9els diff\u00e8rent de nos attentes pr\u00e9sentes de fa\u00e7on importante dans le prospectus en date du 21 avril 2017, sous la rubrique \u00ab\u2009Facteurs de risque\u2009\u00bb. Par cons\u00e9quent, nous ne pouvons garantir la r\u00e9alisation des \u00e9nonc\u00e9s prospectifs. Par ailleurs, nous ne nous engageons aucunement \u00e0 mettre \u00e0 jour ces \u00e9nonc\u00e9s prospectifs, m\u00eame si de nouveaux renseignements devenaient disponibles, \u00e0 la suite d\u2019\u00e9v\u00e9nements futurs ou pour toute autre raison, \u00e0 moins d\u2019y \u00eatre tenus en vertu des lois et r\u00e8glements applicables aux valeurs mobili\u00e8res.<\/p>\n<p><em>La Bourse de croissance TSX et son fournisseur de services de r\u00e9glementation (au sens attribu\u00e9 \u00e0 ce terme dans les politiques de la Bourse de croissance TSX) n\u2019assument aucune responsabilit\u00e9 quant \u00e0 la pertinence ou \u00e0 l\u2019exactitude du pr\u00e9sent communiqu\u00e9.<\/em><\/p>\n<p><strong>Contact\u00a0:<br \/>\n<\/strong>Dr Andr\u00e9 P. Boulet, PhD<br \/>\nChef de la direction scientifique<br \/>\nGroupe Sant\u00e9 Devonian inc.<br \/>\nT\u00e9l\u00e9phone : (514) 248-7509<br \/>\nCourriel :\u00a0<a href=\"mailto:apboulet@groupedevonian.com\">apboulet@groupedevonian.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DEVONIAN PR\u00c9SENTERA LES R\u00c9SULATS CLINIQUES DE LA PHASE 2 DU THYKAMINE\u2122 AU 6th DERMATOLOGY DRUG DEVELOPMENT SUMMIT FOR INFLAMMATORY SKIN DISEASES. QU\u00c9BEC, le\u00a0 12 octobre, 2022\u2013 Groupe Sant\u00e9 Devonian inc. (\u00ab Devonian \u00bb ou la \u00ab Soci\u00e9t\u00e9 \u00bb) (TSXv: GSD ; OTCQB: DVHGF), une soci\u00e9t\u00e9 biopharmaceutique botanique en stade avanc\u00e9 de d\u00e9veloppement ax\u00e9e sur l\u2019\u00e9laboration [&hellip;]<\/p>\n","protected":false},"author":5,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[69,35],"tags":[],"class_list":["post-7233","post","type-post","status-publish","format-standard","hentry","category-2022-fr","category-communiques-de-presse"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>DEVONIAN PR\u00c9SENTERA LES R\u00c9SULATS CLINIQUES DE LA PHASE 2 DU THYKAMINE\u2122 AU 6th DERMATOLOGY DRUG DEVELOPMENT SUMMIT FOR INFLAMMATORY SKIN DISEASES - DEVONIAN HEALTH GROUP INC.<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/groupedevonian.com\/fr\/devonian-presentera-les-resulats-cliniques-de-la-phase-2-du-thykamine-au-6th-dermatology-drug-development-summit-for-inflammatory-skin-diseases\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"DEVONIAN PR\u00c9SENTERA LES R\u00c9SULATS CLINIQUES DE LA PHASE 2 DU THYKAMINE\u2122 AU 6th DERMATOLOGY DRUG DEVELOPMENT SUMMIT FOR INFLAMMATORY SKIN DISEASES - DEVONIAN HEALTH GROUP INC.\" \/>\n<meta property=\"og:description\" content=\"DEVONIAN PR\u00c9SENTERA LES R\u00c9SULATS CLINIQUES DE LA PHASE 2 DU THYKAMINE\u2122 AU 6th DERMATOLOGY DRUG DEVELOPMENT SUMMIT FOR INFLAMMATORY SKIN DISEASES. QU\u00c9BEC, le\u00a0 12 octobre, 2022\u2013 Groupe Sant\u00e9 Devonian inc. (\u00ab Devonian \u00bb ou la \u00ab Soci\u00e9t\u00e9 \u00bb) (TSXv: GSD ; OTCQB: DVHGF), une soci\u00e9t\u00e9 biopharmaceutique botanique en stade avanc\u00e9 de d\u00e9veloppement ax\u00e9e sur l\u2019\u00e9laboration [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/groupedevonian.com\/fr\/devonian-presentera-les-resulats-cliniques-de-la-phase-2-du-thykamine-au-6th-dermatology-drug-development-summit-for-inflammatory-skin-diseases\/\" \/>\n<meta property=\"og:site_name\" content=\"DEVONIAN HEALTH GROUP INC.\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-12T13:15:08+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-01-05T15:07:17+00:00\" \/>\n<meta name=\"author\" content=\"acxdev\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"acxdev\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/groupedevonian.com\\\/fr\\\/devonian-presentera-les-resulats-cliniques-de-la-phase-2-du-thykamine-au-6th-dermatology-drug-development-summit-for-inflammatory-skin-diseases\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/groupedevonian.com\\\/fr\\\/devonian-presentera-les-resulats-cliniques-de-la-phase-2-du-thykamine-au-6th-dermatology-drug-development-summit-for-inflammatory-skin-diseases\\\/\"},\"author\":{\"name\":\"acxdev\",\"@id\":\"https:\\\/\\\/groupedevonian.com\\\/fr\\\/#\\\/schema\\\/person\\\/ff9b4cc2d46ac4fb34e4f4641825f159\"},\"headline\":\"DEVONIAN PR\u00c9SENTERA LES R\u00c9SULATS CLINIQUES DE LA PHASE 2 DU THYKAMINE\u2122 AU 6th DERMATOLOGY DRUG DEVELOPMENT SUMMIT FOR INFLAMMATORY SKIN DISEASES\",\"datePublished\":\"2022-10-12T13:15:08+00:00\",\"dateModified\":\"2024-01-05T15:07:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/groupedevonian.com\\\/fr\\\/devonian-presentera-les-resulats-cliniques-de-la-phase-2-du-thykamine-au-6th-dermatology-drug-development-summit-for-inflammatory-skin-diseases\\\/\"},\"wordCount\":976,\"publisher\":{\"@id\":\"https:\\\/\\\/groupedevonian.com\\\/fr\\\/#organization\"},\"articleSection\":[\"2022\",\"Communiqu\u00e9s de presse\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/groupedevonian.com\\\/fr\\\/devonian-presentera-les-resulats-cliniques-de-la-phase-2-du-thykamine-au-6th-dermatology-drug-development-summit-for-inflammatory-skin-diseases\\\/\",\"url\":\"https:\\\/\\\/groupedevonian.com\\\/fr\\\/devonian-presentera-les-resulats-cliniques-de-la-phase-2-du-thykamine-au-6th-dermatology-drug-development-summit-for-inflammatory-skin-diseases\\\/\",\"name\":\"DEVONIAN PR\u00c9SENTERA LES R\u00c9SULATS CLINIQUES DE LA PHASE 2 DU THYKAMINE\u2122 AU 6th DERMATOLOGY DRUG DEVELOPMENT SUMMIT FOR INFLAMMATORY SKIN DISEASES - DEVONIAN HEALTH GROUP INC.\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/groupedevonian.com\\\/fr\\\/#website\"},\"datePublished\":\"2022-10-12T13:15:08+00:00\",\"dateModified\":\"2024-01-05T15:07:17+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/groupedevonian.com\\\/fr\\\/devonian-presentera-les-resulats-cliniques-de-la-phase-2-du-thykamine-au-6th-dermatology-drug-development-summit-for-inflammatory-skin-diseases\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/groupedevonian.com\\\/fr\\\/devonian-presentera-les-resulats-cliniques-de-la-phase-2-du-thykamine-au-6th-dermatology-drug-development-summit-for-inflammatory-skin-diseases\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/groupedevonian.com\\\/fr\\\/devonian-presentera-les-resulats-cliniques-de-la-phase-2-du-thykamine-au-6th-dermatology-drug-development-summit-for-inflammatory-skin-diseases\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/groupedevonian.com\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"DEVONIAN PR\u00c9SENTERA LES R\u00c9SULATS CLINIQUES DE LA PHASE 2 DU THYKAMINE\u2122 AU 6th DERMATOLOGY DRUG DEVELOPMENT SUMMIT FOR INFLAMMATORY SKIN DISEASES\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/groupedevonian.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/groupedevonian.com\\\/fr\\\/\",\"name\":\"DEVONIAN HEALTH GROUP INC.\",\"description\":\"Botanical pharmaceutical corporation\",\"publisher\":{\"@id\":\"https:\\\/\\\/groupedevonian.com\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/groupedevonian.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/groupedevonian.com\\\/fr\\\/#organization\",\"name\":\"Groupe Sant\u00e9 Devonian inc.\",\"alternateName\":\"Groupe Sant\u00e9 Devonian inc.\",\"url\":\"https:\\\/\\\/groupedevonian.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/groupedevonian.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/groupedevonian.com\\\/wp-content\\\/uploads\\\/2022\\\/05\\\/logo-devonian-2x.png\",\"contentUrl\":\"https:\\\/\\\/groupedevonian.com\\\/wp-content\\\/uploads\\\/2022\\\/05\\\/logo-devonian-2x.png\",\"width\":309,\"height\":183,\"caption\":\"Groupe Sant\u00e9 Devonian inc.\"},\"image\":{\"@id\":\"https:\\\/\\\/groupedevonian.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/groupedevonian.com\\\/fr\\\/#\\\/schema\\\/person\\\/ff9b4cc2d46ac4fb34e4f4641825f159\",\"name\":\"acxdev\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/c219016bab8405cb8b5caa8f18b852d553cf083471d4e9dd4a71c4d518cc3a1c?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/c219016bab8405cb8b5caa8f18b852d553cf083471d4e9dd4a71c4d518cc3a1c?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/c219016bab8405cb8b5caa8f18b852d553cf083471d4e9dd4a71c4d518cc3a1c?s=96&d=mm&r=g\",\"caption\":\"acxdev\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"DEVONIAN PR\u00c9SENTERA LES R\u00c9SULATS CLINIQUES DE LA PHASE 2 DU THYKAMINE\u2122 AU 6th DERMATOLOGY DRUG DEVELOPMENT SUMMIT FOR INFLAMMATORY SKIN DISEASES - DEVONIAN HEALTH GROUP INC.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/groupedevonian.com\/fr\/devonian-presentera-les-resulats-cliniques-de-la-phase-2-du-thykamine-au-6th-dermatology-drug-development-summit-for-inflammatory-skin-diseases\/","og_locale":"fr_FR","og_type":"article","og_title":"DEVONIAN PR\u00c9SENTERA LES R\u00c9SULATS CLINIQUES DE LA PHASE 2 DU THYKAMINE\u2122 AU 6th DERMATOLOGY DRUG DEVELOPMENT SUMMIT FOR INFLAMMATORY SKIN DISEASES - DEVONIAN HEALTH GROUP INC.","og_description":"DEVONIAN PR\u00c9SENTERA LES R\u00c9SULATS CLINIQUES DE LA PHASE 2 DU THYKAMINE\u2122 AU 6th DERMATOLOGY DRUG DEVELOPMENT SUMMIT FOR INFLAMMATORY SKIN DISEASES. QU\u00c9BEC, le\u00a0 12 octobre, 2022\u2013 Groupe Sant\u00e9 Devonian inc. (\u00ab Devonian \u00bb ou la \u00ab Soci\u00e9t\u00e9 \u00bb) (TSXv: GSD ; OTCQB: DVHGF), une soci\u00e9t\u00e9 biopharmaceutique botanique en stade avanc\u00e9 de d\u00e9veloppement ax\u00e9e sur l\u2019\u00e9laboration [&hellip;]","og_url":"https:\/\/groupedevonian.com\/fr\/devonian-presentera-les-resulats-cliniques-de-la-phase-2-du-thykamine-au-6th-dermatology-drug-development-summit-for-inflammatory-skin-diseases\/","og_site_name":"DEVONIAN HEALTH GROUP INC.","article_published_time":"2022-10-12T13:15:08+00:00","article_modified_time":"2024-01-05T15:07:17+00:00","author":"acxdev","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"acxdev","Dur\u00e9e de lecture estim\u00e9e":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/groupedevonian.com\/fr\/devonian-presentera-les-resulats-cliniques-de-la-phase-2-du-thykamine-au-6th-dermatology-drug-development-summit-for-inflammatory-skin-diseases\/#article","isPartOf":{"@id":"https:\/\/groupedevonian.com\/fr\/devonian-presentera-les-resulats-cliniques-de-la-phase-2-du-thykamine-au-6th-dermatology-drug-development-summit-for-inflammatory-skin-diseases\/"},"author":{"name":"acxdev","@id":"https:\/\/groupedevonian.com\/fr\/#\/schema\/person\/ff9b4cc2d46ac4fb34e4f4641825f159"},"headline":"DEVONIAN PR\u00c9SENTERA LES R\u00c9SULATS CLINIQUES DE LA PHASE 2 DU THYKAMINE\u2122 AU 6th DERMATOLOGY DRUG DEVELOPMENT SUMMIT FOR INFLAMMATORY SKIN DISEASES","datePublished":"2022-10-12T13:15:08+00:00","dateModified":"2024-01-05T15:07:17+00:00","mainEntityOfPage":{"@id":"https:\/\/groupedevonian.com\/fr\/devonian-presentera-les-resulats-cliniques-de-la-phase-2-du-thykamine-au-6th-dermatology-drug-development-summit-for-inflammatory-skin-diseases\/"},"wordCount":976,"publisher":{"@id":"https:\/\/groupedevonian.com\/fr\/#organization"},"articleSection":["2022","Communiqu\u00e9s de presse"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/groupedevonian.com\/fr\/devonian-presentera-les-resulats-cliniques-de-la-phase-2-du-thykamine-au-6th-dermatology-drug-development-summit-for-inflammatory-skin-diseases\/","url":"https:\/\/groupedevonian.com\/fr\/devonian-presentera-les-resulats-cliniques-de-la-phase-2-du-thykamine-au-6th-dermatology-drug-development-summit-for-inflammatory-skin-diseases\/","name":"DEVONIAN PR\u00c9SENTERA LES R\u00c9SULATS CLINIQUES DE LA PHASE 2 DU THYKAMINE\u2122 AU 6th DERMATOLOGY DRUG DEVELOPMENT SUMMIT FOR INFLAMMATORY SKIN DISEASES - DEVONIAN HEALTH GROUP INC.","isPartOf":{"@id":"https:\/\/groupedevonian.com\/fr\/#website"},"datePublished":"2022-10-12T13:15:08+00:00","dateModified":"2024-01-05T15:07:17+00:00","breadcrumb":{"@id":"https:\/\/groupedevonian.com\/fr\/devonian-presentera-les-resulats-cliniques-de-la-phase-2-du-thykamine-au-6th-dermatology-drug-development-summit-for-inflammatory-skin-diseases\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/groupedevonian.com\/fr\/devonian-presentera-les-resulats-cliniques-de-la-phase-2-du-thykamine-au-6th-dermatology-drug-development-summit-for-inflammatory-skin-diseases\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/groupedevonian.com\/fr\/devonian-presentera-les-resulats-cliniques-de-la-phase-2-du-thykamine-au-6th-dermatology-drug-development-summit-for-inflammatory-skin-diseases\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/groupedevonian.com\/fr\/"},{"@type":"ListItem","position":2,"name":"DEVONIAN PR\u00c9SENTERA LES R\u00c9SULATS CLINIQUES DE LA PHASE 2 DU THYKAMINE\u2122 AU 6th DERMATOLOGY DRUG DEVELOPMENT SUMMIT FOR INFLAMMATORY SKIN DISEASES"}]},{"@type":"WebSite","@id":"https:\/\/groupedevonian.com\/fr\/#website","url":"https:\/\/groupedevonian.com\/fr\/","name":"DEVONIAN HEALTH GROUP INC.","description":"Botanical pharmaceutical corporation","publisher":{"@id":"https:\/\/groupedevonian.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/groupedevonian.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/groupedevonian.com\/fr\/#organization","name":"Groupe Sant\u00e9 Devonian inc.","alternateName":"Groupe Sant\u00e9 Devonian inc.","url":"https:\/\/groupedevonian.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/groupedevonian.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/groupedevonian.com\/wp-content\/uploads\/2022\/05\/logo-devonian-2x.png","contentUrl":"https:\/\/groupedevonian.com\/wp-content\/uploads\/2022\/05\/logo-devonian-2x.png","width":309,"height":183,"caption":"Groupe Sant\u00e9 Devonian inc."},"image":{"@id":"https:\/\/groupedevonian.com\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/groupedevonian.com\/fr\/#\/schema\/person\/ff9b4cc2d46ac4fb34e4f4641825f159","name":"acxdev","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/c219016bab8405cb8b5caa8f18b852d553cf083471d4e9dd4a71c4d518cc3a1c?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/c219016bab8405cb8b5caa8f18b852d553cf083471d4e9dd4a71c4d518cc3a1c?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/c219016bab8405cb8b5caa8f18b852d553cf083471d4e9dd4a71c4d518cc3a1c?s=96&d=mm&r=g","caption":"acxdev"}}]}},"_links":{"self":[{"href":"https:\/\/groupedevonian.com\/fr\/wp-json\/wp\/v2\/posts\/7233","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/groupedevonian.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/groupedevonian.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/groupedevonian.com\/fr\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/groupedevonian.com\/fr\/wp-json\/wp\/v2\/comments?post=7233"}],"version-history":[{"count":2,"href":"https:\/\/groupedevonian.com\/fr\/wp-json\/wp\/v2\/posts\/7233\/revisions"}],"predecessor-version":[{"id":7240,"href":"https:\/\/groupedevonian.com\/fr\/wp-json\/wp\/v2\/posts\/7233\/revisions\/7240"}],"wp:attachment":[{"href":"https:\/\/groupedevonian.com\/fr\/wp-json\/wp\/v2\/media?parent=7233"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/groupedevonian.com\/fr\/wp-json\/wp\/v2\/categories?post=7233"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/groupedevonian.com\/fr\/wp-json\/wp\/v2\/tags?post=7233"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}